Who are Plendil's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Cardene, Coniel, Cinalong, Cleviprex, Sular, Dynacirc.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/felodipine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Plendil — Competitive Intelligence Brief

Plendil (FELODIPINE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Dihydropyridine Calcium Channel Blocker [EPC]. Area: Cardiovascular.

marketed Dihydropyridine Calcium Channel Blocker [EPC] Voltage-dependent T-type calcium channel subunit alpha-1H Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Plendil (FELODIPINE) — AstraZeneca. Plendil works by blocking calcium channels in blood vessel walls, causing them to relax and widen, which lowers blood pressure.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Plendil TARGET	FELODIPINE	AstraZeneca	marketed	Dihydropyridine Calcium Channel Blocker [EPC]	Voltage-dependent T-type calcium channel subunit alpha-1H	1991-01-01
Cardene	NICARDIPINE	Hikma Intl Pharms	marketed	Dihydropyridine Calcium Channel Blocker	Voltage-dependent T-type calcium channel subunit alpha-1H	1988-01-01
Coniel	BENIDIPINE		marketed	benidipine	Voltage-dependent T-type calcium channel subunit alpha-1H, Voltage-gated L-type calcium channel
Cinalong	CILNIDIPINE		phase 3	cilnidipine	Voltage-dependent N-type calcium channel subunit alpha-1B, Voltage-dependent T-type calcium channel subunit alpha-1H, Voltage-gated L-type calcium channel
Cleviprex	CLEVIDIPINE	Chiesi	marketed	Dihydropyridine Calcium Channel Blocker [EPC]	Voltage-dependent L-type calcium channel subunit alpha-1C	2008-01-01
Sular	NISOLDIPINE	Azurity	marketed	Dihydropyridine Calcium Channel Blocker [EPC]	Voltage-dependent L-type calcium channel subunit alpha-1C	1995-01-01
Dynacirc	ISRADIPINE	Smithkline Beecham	marketed	Dihydropyridine Calcium Channel Blocker [EPC]	Voltage-dependent L-type calcium channel subunit alpha-1D	1990-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Dihydropyridine Calcium Channel Blocker [EPC] class)

Pfizer · 2 drugs in this class
· 1 drug in this class
AstraZeneca · 1 drug in this class
Azurity · 1 drug in this class
Chiesi · 1 drug in this class
Smithkline Beecham · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Plendil — Competitive Intelligence Brief. https://druglandscape.com/ci/felodipine. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab